Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Oct;13(10):1568-75.
doi: 10.1093/annonc/mdf273.

A Multicentre, Randomised Phase III Trial Comparing Protracted Venous Infusion (PVI) 5-fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin C in Patients With Inoperable Oesophago-Gastric Cancer

Affiliations
Free article
Clinical Trial

A Multicentre, Randomised Phase III Trial Comparing Protracted Venous Infusion (PVI) 5-fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin C in Patients With Inoperable Oesophago-Gastric Cancer

N C Tebbutt et al. Ann Oncol. .
Free article

Abstract

Background: This randomised study compared protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin C (MMC) in patients with advanced oesophago-gastric cancer.

Patients and methods: Two hundred and fifty-four patients with adenocarcinoma, squamous cell carcinoma or undifferentiated carcinoma involving the oesophagus, oesophago-gastric junction or the stomach were randomised. The major end points were tumour response, survival, toxicity and quality of life.

Results: The median age of patients treated was 72 years and the two arms were well-balanced for baseline demographic factors. The overall response rate was 16.1% [95% confidence interval (CI) 9.5% to 22.7%] in patients treated with PVI 5-FU alone compared with 19.1% (95% CI 12.0% to 26.0%) for those treated with PVI 5-FU plus MMC (P = 0.555). Median time to treatment failure was 3.9 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P = 0.195). Median survival was 6.3 months for PVI 5-FU and 5.3 months for PVI 5-FU plus MMC (P = 1.0). Toxicity was mild for both treatments. Symptomatic benefit measured by improvement in pain control, weight loss, dysphagia and oesophageal reflux was observed in over 64% of patients in each arm. Quality of life scores were comparable in each arm.

Conclusions: PVI 5-FU is a safe, effective form of palliation for patients with advanced oesophago-gastric cancer although the addition of MMC adds little extra benefit.

Similar articles

See all similar articles

Cited by 22 articles

See all "Cited by" articles

MeSH terms

Feedback